Skip to main content
OpenTrials

Clinical trial condition

Hemostatic Disorders

Explore clinical trials studying Hemostatic Disorders. Study availability and eligibility vary by location and protocol.

3,079 public trials 581 recruiting studies
Refine in advanced search Browse all conditions

Hemostatic Disorders trial results

Completed

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00002878

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • University of California San Diego Cancer Center La Jolla, California, United States
  • UCSF Cancer Center and Cancer Research Institute San Francisco, California, United States
  • CCOP - Christiana Care Health Services Wilmington, Delaware, United States
  • Walter Reed Army Medical Center Washington D.C., District of Columbia, United States
View all 40 locations
View Trial Details
Completed

Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients

NCT03001804

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Landeskrankenhaus Kirchdorf Kirchdorf, Austria
  • Klinikum Klagenfurt am Wörthersee Klagenfurt, Austria
  • Kepleruniversitätsklinikum GmbH, Hämatologie und Internistische Onkologie Linz, Austria
  • Ordensklinikum Linz GmbH Elisabethinen Linz, Austria
View Trial Details
Completed

agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

NCT04754100

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Norton Cancer Institute - St. Matthews - Medical Oncology/Hematology Candida Louisville, Kentucky, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • University of Cincinnati Cancer Center Cincinnati, Ohio, United States
View Trial Details
Completed

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT01734928

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Southern Cancer Center Mobile, Alabama, United States
  • Arizona Oncology Tucson, Arizona, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • Alta Bates Comprehensive Cancer Center Berkeley, California, United States
View all 321 locations
View Trial Details
Completed

Corneal Toxicity in Patients Treated by Belantamab Mafodotin

NCT05887206

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • CHU Dijon Dijon, France
  • CHU de Limoges - Hôpital Dupuytren Limoges, France
  • HCL- Croix Rousse Lyon, France
  • Clinique Monticelli-Vélodrome Marseille, France
View Trial Details

Related conditions